Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease (NCT05894343)
Long-term Follow-up of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease
🩺 Plain-English Summary (8th-Grade Level)
The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (1 items) and avoid the listed exclusions (1 items).
Location: Yale University — New Haven, Connecticut
Age range: 25 Years to 86 Years
🧪 Interventions in This Study
- AAV-GAD (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (6 Sites)
- Yale University — New Haven, Connecticut
- Henry Ford West Bloomfield Hospital — West Bloomfield, Michigan
- Weill Cornell Medicine — New York, New York
- Columbia University Irving Medical Center — New York, New York
- Thomas Jefferson University — Philadelphia, Pennsylvania
- West Virginia University — Morgantown, West Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson's Disease
- Genotypic Influences on Network Progression in Parkinson's Disease — Manhasset, New York
- Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics — Boston, Massachusetts
- Non-invasive VNS for Parkinson's Gait — Hines, Illinois
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Phoenix, Arizona
- Modifiable Variables in Parkinsonism (MVP) — Kenmore, Washington
Explore by condition: All Parkinson's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.